Reach of State-Mandated Insurance Coverage for Fertility Preservation in Patients With Cancer
Purpose Fertility preservation (FP) before cancer treatment effectively reduces iatrogenic infertility. Twenty-three states and the District of Columbia have passed insurance mandates for medically indicated FP coverage, but empiric data on population reach are lacking. We assessed the reach of California's mandate among young patients with cancer and sought to identify if social determinants of health (SDOH) are associated with mandate eligibility. Methods A retrospective cohort study was conducted of all female patients age 0-42 years and male patients age 0-49 years newly diagnosed with cancer at a National Cancer Institute–designated Comprehensive Cancer Center between 2021 and 2024. SDOH included sex, age, race, ethnicity, primary language, and Social Vulnerability Index (SVI). The primary outcome was eligibility for FP coverage under California's mandate. Secondary outcomes included insurer confirmation of FP benefits and time required for benefit verification. Results Of 903 patients, 18% were eligible for state-mandated FP benefits. Ineligibility was due to insurance by Medicaid (49%), ineligible commercial plans (37%), military-based plans (9%), federal-employee plans (2%), or being uninsured (3%). Non–English-speaking patients were 64% less likely to be eligible versus English-speaking patients (adjusted relative risk, 0.36 [95% CI, 0.17 to 0.75]) in adjusted analysis. Subgroup analyses showed that eligible patients differed significantly from ineligible Medicaid-insured patients by race, primary language, and SVI, but did not differ from ineligible commercially insured patients. Among patients with plans subject to the mandate, insurers inaccurately reported that they had no FP coverage 28% of the time. Benefit verification required a median of 45 minutes per patient (range, 9-350 minutes, interquartile range, 25-80). These secondary outcomes differed significantly by insurer ( P < .001). Conclusion California's mandate excludes most at-risk patients with cancer and perpetuates disparities in access. Future work in oncofertility health policy must consider mandate design and downstream implementation to eliminate barriers to care.
Authors
- An Zhang (ORCID: https://orcid.org/0009-0005-7134-8981)
- Sally A.D. Romero (ORCID: https://orcid.org/0000-0001-6028-4111)
- Nia Palmer
- Hui-Chun Irene Su (ORCID: https://orcid.org/0000-0002-6671-5151)
- Kelly M. Chacón (ORCID: https://orcid.org/0000-0002-7484-7920)
- Sara B. McMenamin (ORCID: https://orcid.org/0000-0003-3235-6936)
- Helen Palomino (ORCID: https://orcid.org/0000-0003-2140-7398)
- Bonnie N. Kaiser (ORCID: https://orcid.org/0000-0003-0742-1302)
- Kristina Nguyen (ORCID: https://orcid.org/0009-0000-0638-2327)
- Dunay Bach
- Keri Tomechko (ORCID: https://orcid.org/0009-0007-3472-7864)
- Lourdes Murcia
- Ricardo E. Flores Ortega
- Blanca Equihua
Institutions
- San Diego State University (US)
- Riverside University Health System - Medical Center (US)
- University of California San Diego (US)
- Cancer Resource Center of the Desert (US)
- Moores Cancer Center (US)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2026-11-20
- DOI
- https://doi.org/10.1200/jco-26-01296
- Primary Topic
- Reproductive Biology and Fertility
- Type
- article
- Field-Weighted Citation Impact
- 0.00